Axion’s MEA systems can model complex brain activity and heartbeats in a dish. As a result, toxicity and efficacy can be assessed earlier in the drug development process, and with greater sensitivity and accuracy. These comprehensive system-level evaluations provide an in vitro solution to reducing animal testing, a key objective of the Tox21 and REACH initiatives.
Axion’s MEA systems provide a label-free in vitro platform for direct measurement of electrical activity in neurons and cardiomyocytes, while the efficiency and convenience of Axion’s standard MEA plates facilitate use for screening-level applications. The large number of electrodes per well reveals detailed information about systems-level signal propogation.
CNS World Summit – Philadelphia, PA Sept 9-11
Axion BioSystems is a proud Sponsor of the CNS World Summit being held in Philadelphia, PA Sept 9-11. We’re looking forward to engaging conversations with speakers and attendees during the 9th Neurodegenerative Conditions Research & Development conference. Take a look at our Applications page to see how the Maestro can add immeasurable value to YOUR neuroscience research.
Software update – AxIS 2.1
AxIS 2.1 is Axion’s new software platform for MEA data acquisition and analysis. Featuring enhanced, integrated cardiac and neural analysis, faster data processing, and plate maps to record and view well treatments, AxIS 2.1 provides significant new functionality that will continue to empower your MEA experiments.